
Eli Lilly's Q3 volume growth beats pricing pressure, raising 2026 revenue guidance with a $1,600 price target.
Eli Lilly reported a 53% volume increase in Q3 despite a 15% drop in realized prices, prompting management to raise 2026 revenue guidance to $91–92 billion. The company's promising drug Retatrutide, currently in Phase 3 trials, supports future growth...




